Laboratory Medicine banner
     
HomeFaculty › Colin C. Pritchard MD, PhD

Colin C. Pritchard MD, PhD

photo Dr. Colin Pritchard

Associate Professor, Genetics
Associate Director, Genetics and Solid Tumors Laboratory

Research Program

The Pritchard laboratory is focused on three areas related to cancer molecular diagnostics:

1) Cancer molecular diagnostics development for precision medicine

A primary focus is to develop innovative molecular diagnostics for the detection of germline and somatic mutations that guide therapeutic decision making. As examples, the lab has developed and validated the "ColoSeq™" and the "UW‑OncoPlex™" assays, which are clinically available at the University of Washington. UW‑OncoPlex™ is a multiplexed next generation sequencing gene panel that detects mutations in tumor tissue in 260 genes related to cancer treatment decision making.

My laboratory is actively exploring noninvasive methods for sampling cancer mutations including cell‑free microRNA, cell‑free DNA, and circulating tumor cell‑associated nucleic acids. We are investigating pre‑analytic and biological variation that impact serum and plasma circulating nucleic acid biomarker measurements to inform the appropriate use and interpretation of "liquid biopsy" blood tests.

2) Prostate cancer precision medicine

In collaboration with members of the Pacific Northwest Prostate Cancer SPORE and the PCF/SU2C prostate cancer international dream team my laboratory is working in several areas to make precision medicine a reality for men with prostate cancer. Projects include application of UW‑OncoPlex™ for men with prostate cancer, characterization of hypermutation as a predictive biomarker in advanced prostate cancer, and development of novel non‑invasive diagnostics to guide therapy in advanced disease.

3) Improving diagnosis of Lynch syndrome

Lynch syndrome is among the most common causes of genetic predisposition to cancer, and yet it remains underdiagnosed. It is characterized by genetic defects in mismatch DNA repair genes leading to microsatellite instability (MSI) and hypermutation in tumors. My lab has developed methods to detect MSI and hypermutation from next generation sequencing (NGS) data. Using this technology we developed the first ever first ever tumor‑based NGS test for Lynch syndrome (ColoSeq Tumor).

Investigator

Dr. Pritchard is an Assistant Professor of Laboratory Medicine. He is also the associate director of the clinical molecular genetics laboratory in Laboratory Medicine at the University of Washington Medical Center, where he focuses on oncology molecular diagnostics.

Selected Publications

  1. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussein M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin M‑E, AlDubayan S, Han GC, Beightol M, Morrissey C, Noteboom J, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff P, Solit D, Robson M, Van Allen EM, Offit K, DeBono J, and Nelson PS. Inherited DNA‑Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016). New England Journal of Medicine. 375:443‑53.
    [PubMed]
  2. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. (2016) . Nature Medicine. 22:1342‑1350.
    [PubMed]
  3. Cowen (Shiovitz) S, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WHM, Lin EH, Cohn, DE, Goodfellow PJ, Arnold MW, Chapelle Adl, Pearlman R, Hampel H, and Pritchard CC. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors with 2 or More Somatic Mutations in Mismatch Repair Genes. (2016) Gastroenterology. 151:440‑447.
    [PubMed]
  4. Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS and Pritchard CC. Pilot study of clinical targeted next generation sequencing for prostate cancer: consequences for treatment and genetic counseling. (2016). Prostate. 76: 2016; 1303‑11.
    [PubMed]
  5. Shirts BH, Casadei S, Jacobson AL, Lee MK, Gulsuner S, Bennett RL, Miller M, Hall SA, Hampel H, Hisama F, Naylor LV, Goetsch C, Leppig K, Tait JF, Scroggins S, Turner E, Livingston R, Salipante S, King M‑C, Walsh T, and Pritchard CC. Improving performance of multigene panels for genomic analysis of cancer predisposition. (2016). Genetics in Medicine.
    [PubMed]
  6. Swisher EM, Harrell M, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli K, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. (2016). JAMA Oncology. 2:370‑2.
    [PubMed]
  7. Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Biallelic Inactivation of BRCA2 in Platinum‑sensitive Metastatic Castration‑resistant Prostate Cancer. (2016) European Journal of Urology.
    [PubMed]
  8. Blau CA, Ramirez AB, Blau S, Pritchard CC, Dorschner MO, Schmechel SC, Martins TJ, Mahen EM, Burton KA, Komashko VM, Radenbaugh AJ, Dougherty K, Thomas A, Miller CP, Annis J, Fromm JR, Song C, Chang E, Howard K, Austin S, Schmidt RA, Linenberger ML, Becker PS, Senecal FM, Mecham BH, Lee SI, Madan A, Ronen R, Dutkowski J, Heimfeld S, Wood BL, Stilwell JL, Kaldjian EP, Haussler D, Zhu J. A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple‑Negative Breast Cancer. (2016). J Natl Compr Canc Netw. 14:8‑17.
    [PubMed]
  9. Jour G, Liu Y, Ricciotti R, Pritchard CC, Hoch B. Glandular Differentiation in Dedifferentiated Chondrosarcoma: Molecular Evidence of a Rare Phenomenon. (2015). Human Pathology. 46:1398‑404.
    [PubMed]
  10. Goodfellow PJ, Billingsley CC, Lankes HA, Ali S, Cohn DE, Broaddus RJ, Ramirez N, Pritchard CC, Hampel H, Chassen AS, Simmons LV, Schmidt AP, Gao F, Brinton LA, Backes F, Landrum LM, Geller MA, DiSilvestro PA, Pearl ML, Lele SB, Powell MA, Zaino RJ, Mutch D. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. (2015) Journal of Clinical Oncology. 2015 33:4301‑8.
    [PubMed]
  11. Baik C, Wu D, Smith C, Martins R, and Pritchard CC. Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication. (2015). Journal of Thoracic Oncology. 10:e97‑e99.
    [PubMed]
  12. Hempelmann JA, Scroggins SM, Pritchard CC, Salipante SJ. MSIplus for Integrated Colorectal Cancer Molecular Testing by Next‑Generation Sequencing. (2015). Journal of Molecular Diagnostics. 17:705‑14.
    [PubMed]
  13. Robinson D, Van Allen EM, Wu Y, Schultz N., Lonigro RJ, Mosquera J, Montgomery R, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida WM, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Scher HI, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Chew FS, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Demichelis F, Elemento O, Robinson BD, Sboner A, Schiffman MA, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Heath E, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. (2015). Cell. 161:1215-1228.
    [PubMed]
  14. Gallego CJ, Mvundura M, Shirts BH, Bennette CS, Guzauskas G, Amendola L, Horike‑Pyne M, Hisama F, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next‑generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost‑effectiveness analysis. (2015). Journal of Clinical Oncology. 33:2084‑91.
    [PubMed]
  15. Zhang MY, Churpek JE, Walsh T, Lee MK, Keel SB, Loeb KR, Gulsuner S, Pritchard CC, Forouhar M, Gyurkocza B, Schwartz B, Neistadt B, Marquez R, Mariani C, Coats SA, Hofmann I, Williams DA, Fleming MD, Abkowitz JL, Horwitz MS, Godley LA, King M‑C, and Shimamura A. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. (2015). Nature Genetics. 47:180‑5.
    [PubMed]
  16. Zhang MY, Keel SB, Walsh T, Lee MK, Gulsuner M, Watts AC, Pritchard CC, Salipante S, Jeng MR, Hofmann I, Williams DA, Fleming MD, Abkowitz JL, King M‑C, and Shimamura A. Genomic analysis of bone marrow failure and myelodysplastic syndromes reveals phenotypic and diagnostic complexity. (2014). Haematologica. 100:42‑8.
    [PubMed]
  17. Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, Chapelle Adl, and Pritchard CC. Colon and Endometrial Cancers with Mismatch Repair Deficiency can Arise from Somatic, Rather Than Germline, Mutations. (2014). Gastroenterology. 147:1308‑1316.
    [PubMed]
  18. Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS. Complex MSH2 and MSH6 Mutations in Hypermutated Microsatellite Unstable Advanced Prostate Cancer. (2014). Nature Communications. 5:4988.
    [PubMed]
  19. Salipante S, Scroggins S, Hampel HL, Turner EH, and Pritchard CC. Microsatellite Instability Detection By Next Generation Sequencing. (2014). Clinical Chemistry. 60:1192‑9.
    [PubMed]
  20. Jour G, Scarborough JD, Jones RL, Loggers E, Pollack SM, Pritchard CC, Hoch BL. Molecular Profiling of Soft Tissue Sarcomas Using Next‑Generation Sequencing: A Pilot Study Towards Precision Therapeutics. (2014) Human Pathology. 45:1563‑71.
    [PubMed]
  21. Pritchard CC, Salipante SJ, Koehler K, Smith C, Scroggins S, Wood B, Wu D, Lee MK, Dintzis S, Adey A, Liu Y, Eaton KD, Martins R, Stricker K, Margolin KA, Hoffman N, Churpek JE, Tait JF, King M‑C, and Walsh T. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. (2014) Journal of Molecular Diagnostics. 16:56‑67.
    [PubMed]
  22. Cheng HH, Yi H‑S, Kim Y, Kroh E, Chien J, Eaton KD, Goodman MT, Tait JF, Tewari M, and Pritchard CC. Plasma processing conditions substantially influence circulating microRNA biomarker levels. (2013). PLoS ONE. 8:e64795.
    [PubMed]
  23. Hiatt JB, Pritchard CC, Salipante SJ, O'Roak BJ, and Shendure J. Single molecule molecular inversion probes for targeted, high‑accuracy detection of low‑frequency variation. Genome Research. (2013) 23:843‑54.
    [PubMed]
  24. Pritchard C, Cheng H, Tewari M. MicroRNA Profiling: Approaches and Considerations. Nature Reviews Genetics. (2012) 13:358‑69.
    [PubMed]
  25. Pritchard C, Kroh E, Wood K, Arroyo J, Miyagi M, Dougherty K, Tait J, Tewari M. Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies. Cancer Prevention Research (Phila). (2012) 5:492‑7.
    [PubMed]
  26. Pritchard C, Smith C, Salipante SJ, Lee MK, Thornton AM, Nord AS, Gulden C, Kupfer SS, Swisher E, Bennett RL, Novetsky AP, Jarvik GP, Olopade OI, Goodfellow PJ, King M‑C, Tait JF, and Walsh T. ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing. Journal of Molecular Diagnostics. (2012) 14:357‑66.
    [PubMed]

Last updated: 11/29/2016

HomeFaculty › Colin C. Pritchard MD, PhD

Return to Top